Grant Awarded to Study Motor Recovery in Stroke Survivors

Translate to Spanish or other 102 languages!

Dr. Michael R. Dobbs, chair of the Department of Neurology, UTRGV School of Medicine, and Dr. Kelsey Baker, assistant professor, Department of Neuroscience, UTRGV School of Medicine. (UTRGV Photos)
Dr. Michael R. Dobbs, chair of the Department of Neurology, UTRGV School of Medicine, and Dr. Kelsey Baker, assistant professor, Department of Neuroscience, UTRGV School of Medicine. (UTRGV Photos)

Mega Doctor News

- Advertisement -

By Maria Gonzalez

RIO GRANDE VALLEY, Texas – Dr. Michael R. Dobbs, professor and chair of the Department of Neurology in the UTRGV School of Medicine, has been awarded a $443,963 grant to research the motor recovery, along with the brain and spine degeneration, of 30 stroke survivors over the next three years. 

The grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS), which is part of the federal government’s National Institutes of Health (NIH).  

- Advertisement -

Dobbs said the R15 NIH grant will allow him to study whether degeneration after a stroke affects some areas of the brain more progressively than others, and whether that degeneration extends to the level of the spinal cord. 

“We want to determine how this degeneration impacts the ability to move the first three months after a stroke,” Dobbs said.

The project, titled “Role of Alternative Sensorimotor Pathway Degeneration in Motor Function of in Acute Stroke,” will be led by principal investigator Dobbs, and co-PI Dr. Kelsey Baker, assistant professor in the Department of Neuroscience at the UTRGV School of Medicine. 

Baker said it is estimated that, by 2030, an additional 3.4 million adults will experience a stroke.

- Advertisement -

“White Hispanic males are projected to experience the highest rates,” she said, “In addition, preliminary estimates from our work suggest that stroke is a particular concern in South Texas and the Rio Grande Valley.” 

Dr. Thomas Spencer, associate vice president for UTRGV’s Division of Research, said the division fully supports the work Dobbs and his research team are doing.

“Their search for advancements in the diagnosis and treatment of patients needing neurological care is important – and in many cases critical – not just to patients in the Valley, but around the world,” he said.

This federal funding will provide the means to collect high-resolution and advanced neuroimaging protocols (MRI) through one of the first studies to capture neuronal pathway changes in the spinal cord in acute stroke. The study will be conducted at the newly established UTRGV Institute of Neuroscience in Harlingen. 

NEUROLOGY AND NEUROSCIENCE TRAINING FOR THE NEXT GENERATION

NIH grant reviewers called the grant application “a highly translational application from an experienced clinician-scientist that could produce some intriguing new clinical science for stroke survivors, while creating an outstanding training opportunity for students at UTRGV…” 

Dobbs said this Research Enhancement Award Program (REAP) project will provide a valuable opportunity for medical students to be exposed to hypothesis-driven research within the Valley. It also will enhance the UTRGV-NIH research portfolio and provide medical students and undergraduate students opportunities to be at the forefront of research data collection and presentation. 

“Additionally, the work will lead to publications in scientific journals,” Dobbs said, “and could lead to additional funded projects through other NIH mechanisms.”    

The grant lasts through March 31, 2025. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Social Security Administration Corrects Millions of Records in Major Database Cleanup

The Social Security Administration (SSA) announced on October 20, 2026, that it has corrected millions of Social Security number records in what the agency describes as its most comprehensive record-integrity initiative in 91 years.

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.

A UTHealth Houston Physician Turned a Texas Teen’s Frightening Diagnosis into a Champion Title

Two years ago, Geordon Boulware, now 15, was at a routine dental visit in his hometown of Lufkin, Texas, when his dentist discovered he had an abnormal growth on his jaw. After meeting with a local oral surgeon, Geordon and his mom decided to seek treatment in Houston. 

Dr. Lisa Chapa Explains Why Not Every Breast Lump Is Cancer

 Discovering a lump in the breast can cause immediate concern, but many breast abnormalities are not cancerous, according to Dr. Lisa Chapa, a breast surgeon who explained how physicians distinguish benign conditions from breast cancer.
- Advertisement -